C-KIT Messenger RNA and Protein Expression and Mutations in Canine Cutaneous Mast Cell Tumors: Correlations with Post-surgical Prognosis
Overview
Authors
Affiliations
Cutaneous mast cell tumors (MCTs) are among the most common neoplasms in dogs and show a highly variable biologic behavior. Histological grading, cell proliferation markers, and KIT immunohistochemistry are typically used to predict post-surgical prognosis. In the present study, c-KIT messenger RNA (mRNA) expression was measured in canine MCTs and its relationship with tumor grade, immunohistochemical staining pattern, post-surgical prognosis, and mutations was investigated. A significant increase of c-KIT mRNA was observed in MCTs versus healthy skin and surgical margins. Mutations were observed in 8.3% of cases. The KIT staining pattern was investigated for both grading systems. In particular, staining pattern III was associated with grade II (G2) and G3 MCTs, while staining patterns I and II were associated with G1 and G2 MCTs. Considering the 2-tier histological grading, the high grade was mainly associated with pattern III (71%) while the low grade was associated with patterns II (70%) and I (28%). A weak association between the KIT staining pattern and outcome was also observed. The results obtained suggest that c-KIT mRNA is overexpressed in canine MCT, although the fold variations were not associated with the protein localization or complementary DNA mutations. These observations suggested that the 3 events were independent. The histological grading and the KIT staining pattern have prognostic value as previously published. Staining pattern I could be especially helpful in predicting a good prognosis of G2 MCTs. Sequence mutations were not necessarily suggestive of a worse prognosis, but might be useful in choosing a chemotherapy protocol.
Montanucci L, Guidolin E, Lopparelli R, Mucignat G, Pauletto M, Giantin M Vet Sci. 2024; 11(12).
PMID: 39728933 PMC: 11680137. DOI: 10.3390/vetsci11120593.
Muko R, Ojima Y, Matsuda H, Toishi Y, Oikawa M, Shin T Vet Anim Sci. 2024; 25:100361.
PMID: 38947185 PMC: 11214520. DOI: 10.1016/j.vas.2024.100361.
Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.
Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L Vet Sci. 2024; 11(5).
PMID: 38787171 PMC: 11126050. DOI: 10.3390/vetsci11050199.
Immunohistochemical and Molecular Genetic Analysis of Canine Digital Mast Cell Tumours.
Conrad D, Kehl A, Muller T, Klopfleisch R, Aupperle-Lellbach H Animals (Basel). 2023; 13(10).
PMID: 37238124 PMC: 10215161. DOI: 10.3390/ani13101694.
Canine mast cell tumours part I: Clinical and survival outcomes.
Tamlin V, Bottema C, Woolford L, Dobson E, Kessell A, Peaston A Vet Med Sci. 2022; 8(4):1409-1420.
PMID: 35505524 PMC: 9297790. DOI: 10.1002/vms3.812.